» Articles » PMID: 33133384

Diagnostic Value of Serum Human Epididymis Protein 4 in Esophageal Squamous Cell Carcinoma

Overview
Date 2020 Nov 2
PMID 33133384
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Numerous studies have demonstrated that human epididymis protein 4 (HE4) is overexpressed in various malignant tissues including ovarian, endometrial, lung, breast, pancreatic, and gastric cancers. However, no study has examined the diagnostic impact of HE4 in patient with esophageal squamous cell carcinoma (ESCC) until now.

Aim: To analyze the value of four serum tumor markers for the diagnosis of ESCC, and examine the associations of serum levels of HE4 with ESCC patients' clinicopathological characteristics.

Methods: The case group consisted of 80 ESCC patients, which were compared to a control group of 56 patients with benign esophageal disease. Serum levels of HE4, carcinoma embryonic antigen (CEA), alpha fetal protein, and carbohydrate antigen 19-9 (CA19-9) were detected by ELISA. The associations of serum HE4 levels with ESCC patients' clinicopathological characteristics such as gender, tumor location, and pathological stage were also examined after operation.

Results: The result of ELISA showed that serum HE4 level was significantly higher in the patients with ESCC than in the controls, and the staining intensity was inversely correlated with the pathological T and N stages. Serum HE4 levels had a sensitivity of 66.2% and specificity of 78.6% when the cutoff value was set at 3.9 ng/mL. Moreover, the combined HE4 and CA19-9 increased the sensitivity to 83.33%, and interestingly, the combination of HE4 with CEA led to the most powerful sensitivity of 87.5%. Furthermore, A positive correlation was observed between HE4 serum levels and pathological T and N stages ( = 0.0002 and 0.0017, respectively), but there was no correlation between HE4 serum levels and ESCC patient gender ( = 0.4395) or tumor location ( = 0.6777).

Conclusion: The results of this study suggest that detection of serum HE4 levels may be useful in auxiliary diagnosis and evaluation of the progression of ESCC.

Citing Articles

Diagnosis and prognosis prediction of gastric cancer by high-performance serum lipidome fingerprints.

Cai Z, Wang W, Chen D, Chen H, Hu Y, Luo X EMBO Mol Med. 2024; 16(12):3089-3112.

PMID: 39543322 PMC: 11628598. DOI: 10.1038/s44321-024-00169-0.

References
1.
Bie Y, Zhang Z . Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014; 12:169. PMC: 4050396. DOI: 10.1186/1477-7819-12-169. View

2.
Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

3.
Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L . Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012; 419(2):274-80. DOI: 10.1016/j.bbrc.2012.02.008. View

4.
Moore R, Brown A, Miller M, Skates S, Allard W, Verch T . The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108(2):402-8. DOI: 10.1016/j.ygyno.2007.10.017. View

5.
Inada M, Nishimura Y, Ishikawa K, Nakamatsu K, Wada Y, Uehara T . Comparing the 7th and 8th editions of the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system for esophageal squamous cell carcinoma treated by definitive radiotherapy. Esophagus. 2019; 16(4):371-376. DOI: 10.1007/s10388-019-00675-y. View